综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。
The pharmacological actions of histone deacetylase inhibitors and their potential clinical use…
综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。
The pharmacological actions of histone deacetylase inhibitors and their potential clinic…
组蛋白去乙酰酶抑制剂降低抗原提呈小鼠骨髓来源的树突状细胞的活性。
Histone deacetylase inhibitors decrease the antigen presenting activity of murine bone marrow derived dendritic cells.
组蛋白去乙酰酶抑制剂可提高组蛋白的乙酰化水平，并对一些非组蛋白成分产生影响，从而调节某些特定基因的表达。
Histone deacetylase inhibitors increase the acetylation level of histone as well as some non-histone proteins, and specifically modulate some gene expression.
目的：探讨组蛋白去乙酰化酶抑制剂MS- 275诱导人多发性骨髓瘤细胞株u266凋亡的分子机制。
OBJECTIVE: to investigate the molecular mechanisms of histone deacetylase inhibitor MS-275 on apoptosis of human myeloma U266 cell line.
本文主要就组蛋白乙酰转移酶调节基因转录以及组蛋白去乙酰化酶抑制剂促进记忆形成的作用机理进行综述。
In this paper, we reviewed the mechanisms on histone acetyltransferases regulating gene transcription and histone deacetylase inhibitors promoting memory formation.
本文综述了丁酸和植物提取物等饲料添加剂作为组蛋白去乙酰化酶(HDAC)抑制剂在模型动物及畜禽上的研究进展。
This review focused on the advances of the effect of feed additives, such as butyrate and plant extracts, on model animal and livestock as inhibitors of histone deacetylases (HDAC).
认识到开发新颖治疗剂的要求，本发明提供新颖组蛋白去乙酰化酶抑制剂。
In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors.
目的研究组蛋白去乙酰化酶抑制剂MS275对人多发性骨髓瘤细胞U266增殖的影响。
ObjectiveTo investigate the antitumor effect of MS275, a histone deacetylase inhibitor, on growth of the human myeloma cell line U266.
抗肿瘤药罗米地辛是一种有效的组蛋白去乙酰化酶抑制剂，临床 上用于治疗皮肤T细胞淋巴瘤。
Romidepsin is a potent histone deacetylase inhibitor, and is used in the treatment of cutaneous T-cell lymphoma (CTCL).
抗肿瘤药罗米地辛是一种有效的组蛋白去乙酰化酶抑制剂，临床 上用于治疗皮肤T细胞淋巴瘤。
Romidepsin is a potent histone deacetylase inhibitor, and is used in the treatment of cutaneous T-cell lymphoma (CTCL).
应用推荐